Global Hypertrophic Cardiomyopathy Therapeutics Market is segmented By Drug Class (Anticoagulants, Beta Adrenergic Blocking Agents, Antiarrhythmic Agents, Calcium Channel Blockers, Others), By Type of Devices (Defibrillators, Pacemakers, Others), By End User (Hospital Pharmacy, Retail Pharmacy, Clinics, Ambulatory Surgical Centers, Academic and Research Organizations), By Disease Type (Obstructive Hypertrophic Cardiomyopathy, Non-obstructive Hypertrophic Cardiomyopathy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Hypertrophic Cardiomyopathy Therapeutics Market is expected to grow at a high CAGR during the forecast period (2024-2031).
Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease caused due to mutation in sarcomere protein genes, which encodes for the contractile machinery of the heart. This is characterized by an increase in left ventricular wall thickness that causes left ventricular outflow obstruction, myocardial diastolic dysfunction, ischemia, and mitral regurgitation. Symptoms of hypertrophic cardiomyopathy are dyspnea, fatigue, palpitations, chest pain, and syncope.
Market Summary
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Drug Class, By Type of Devices, By End User, By Disease Type, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights - Request Free Sample
Market Dynamics
The demand for Hypertrophic Cardiomyopathy (HCM) therapeutics is expected to grow over the forecast period, due to the increasing prevalence of hypertrophic cardiomyopathy globally. The growing number of studies & R&D in the field of hypertrophic cardiomyopathy treatment by private and government organizations has led to the development of efficient treatment options such as calcium channel blockers and antiarrhythmic agents, this is expected to boost the hypertrophic cardiomyopathy therapeutics market growth during the forecast period.
Increasing Investment in Research and Development
Investment in the research and development of new drugs is further driving market growth. For instance, in 2020, Cytokinetics, a US-based biopharmaceutical company, has started a phase 2 clinical study for the treatment of Cardiomyopathy. The myosin inhibitor was evaluated to enhance the dosing schedule & to analyze the therapeutic window for patients diagineshed with HCM. The study found that the cardiac myosin inhibitor had achieved desired effects and had obtained a steady-state drug movement throughout the body within 14 days. Thus, growing R&D will boost market growth.
Increasing cases related to chronic cardiovascular Ailments drives the market demand
The global hypertrophic cardiomyopathy therapeutics market is expected to have a positive growth opportunity in the coming years due to the elevating demand for effective treatment options. The market growth is attributed to the aggressive occurrence of chronic cardiovascular diseases. The most frequent cause of death among both men and women around the globe have been researched to be heart disease. The demand for effective medications is projected to witness a consistent rise on the back of the increasing prevalence of congestive heart failure. As a result, generating attractive growth prospects for the global hypertrophic cardiomyopathy therapeutics market.
COVID-19 Impact Analysis
COVID-19 pandemic affected the global economy in many terms, such as directly affecting production and demand, supply chain disruption, and financial impact. COVID-19 has directly affected the manufacturers' supply chain across the globe and shut down the production facilities to minimize the risk of virus spread. In addition, the sudden outbreak of COVID-19 has resulted in a decrease in the growth of the hypertrophic cardiomyopathy therapeutics market. According to the American Gastrointestinal and Endoscopic Surgeons (SAGES) and European Association for Endoscopic Surgery (EAES) recommendations hospitals are reducing medical staff members and continuously growing numbers of infected patients have reduced the availability of healthcare professionals and has obstructed logistics supply. With countries coming out of stringent lockdown policies, it is expected to drive hypertrophic cardiomyopathy therapeutics market size in the global market during the forecast period.
Market Segment Analysis
Based on the type of drugs, the hypertrophic cardiomyopathy therapeutics market has been classified into Anticoagulants, Beta Adrenergic Blocking Agents, Antiarrhythmic Agents, Calcium Adrenergic Blocking Agents and Others.
Beta Adrenergic Blocking Agents Segment is forecasted to hold significant market share
Calcium channel blockers or calcium channel antagonists are widely used as antihypertensive drugs which act by reducing the amount of calcium that goes into the cardiac muscle cells and help them to relax. Calcium channel blockers are used to change the heart rate, reduce chest pain, and prevent cerebral vasospasm more effectively compared to beta-blockers in the treatment of cardiovascular disorders. Furthermore, the rising geriatric population and obesity are key factors driving the global market.
Based on the type of devices, the hypertrophic cardiomyopathy therapeutics market can be divided into defibrillators, pacemakers, and others.
Pacemakers devise segments to account for the largest market share
The pacemakers devices account for the largest market share due to the rise in the number of heart failure and hypertrophic cardiomyopathy cases. The pacemaker device is implanted in the chest or abdomen and it helps in controlling abnormal heart rhythms using electrical pulses.
Market Geographical Share
Based on geography, the study analyzes the hypertrophic cardiomyopathy therapeutics market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America is projected to drive the growth of the Hypertrophic Cardiomyopathy (HCM) therapeutics market during the forecast period, due to the increasing prevalence of obesity among the younger population in North America and increase in preference towards a sedentary lifestyle, which are the primary factors driving for hypertrophic cardiomyopathy therapeutics in these regions.
Europe is expected to gain a significant market share over the forecast period, owing to the increasing occurrence of Hypertrophic Cardiomyopathy (HCM) and the increasing number of obese patients in the Europe region. For instance, according to the European Cardiovascular Disease Statistics 2017, the obesity rates are high across both Europe and European Union, including both adults and children. Furthermore, the prevalence of diseases such as diabetes in Europe is high and rapidly increasing.
Market Key Players
The Hypertrophic Cardiomyopathy Therapeutics Market is moderately consolidated competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Sanofi S.A., Astra Zeneca Plc, Pfizer Inc, ADVANZ PHARMA Corp (Concordia Healthcare Corp), Gilead Sciences, Inc. Inc, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd, Novartis AG, Mylan N.V., Bayer AG.
AstraZeneca Plc
Overview:
AstraZeneca Plc is a British-Swedish multinational pharmaceutical and biotechnology company. AstraZeneca specializes in drugs for cardiovascular, metabolic, neurological, gastrointestinal, respiratory, oncology, and infection therapy areas. Some of the key products include cholesterol reducer Crestor, cardiovascular drug Brilinta, acid reflux remedy Nexium, and Symbicort for asthma. AstraZeneca also markets drugs that aim to treat high cholesterol, diabetes, pain, viral diseases, and various cancers. The company has more than 30 factories globally and R&D centres in the UK, US, Sweden, and China, and its products are sold in more than 100 countries. The company has headquarters at the Cambridge Biomedical Campus in Cambridge, England.
Product Portfolio: The company has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Why Purchase the Report?
- Visualize the hypertrophic cardiomyopathy therapeutics market segmentation composition by drug class, disease type, type of devices, end-user application, and region, highlighting the critical commercial assets and players.
- Identify commercial opportunities in the hypertrophic cardiomyopathy therapeutics market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of hypertrophic cardiomyopathy therapeutics market- level 4 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global hypertrophic cardiomyopathy therapeutics market report would provide access to an approx. 57 market data table, 66 figures and 180 pages.
Target Audience
- Service Providers/ Buyers
- Industry Investors/Investment Bankers
- Education & Research Institutes
- Research Professionals
- Emerging Companies
- Manufacturers
